Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenqing Yao

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Plos One|April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPhillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
ACS Medicinal Chemistry Letters|March 16, 2023
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing ApproachMinh H Nguyen, Hai-Fen Ye, Yao Xu, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of INCB126503 as a Potent and Selective FGFR2/3 InhibitorMinh H Nguyen, Anlai Wang, Lisa Truong, et al.
Journal of Medicinal Chemistry|November 10, 2022
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3Artem Shvartsbart, Jeremy J Roach, Michael R Witten, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2022
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approachColin Zhang, Meizhong Xu, Chunhong He, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist and Clinical Candidate INCB106385Chao Qi, Matthew S McCammant, Yong Li, et al.
The Lancet Regional Health. Western Pacific|February 15, 2021
Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in ChinaZhongjie Li, Xuhua Guan, Naiying Mao, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Plos One|April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPhillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
ACS Medicinal Chemistry Letters|March 16, 2023
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing ApproachMinh H Nguyen, Hai-Fen Ye, Yao Xu, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of INCB126503 as a Potent and Selective FGFR2/3 InhibitorMinh H Nguyen, Anlai Wang, Lisa Truong, et al.
Journal of Medicinal Chemistry|November 10, 2022
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3Artem Shvartsbart, Jeremy J Roach, Michael R Witten, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2022
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approachColin Zhang, Meizhong Xu, Chunhong He, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist and Clinical Candidate INCB106385Chao Qi, Matthew S McCammant, Yong Li, et al.
The Lancet Regional Health. Western Pacific|February 15, 2021
Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in ChinaZhongjie Li, Xuhua Guan, Naiying Mao, et al.
Pageof 11